InnovationRx: Positive Clinical Trial Results For Generative AI-Designed Drug

-



Insilico Medicine announced results from a clinical trial of ISM001-055, which the company designed using generative AI in order to treat idiopathic pulmonary fibrosis, a chronic lung disease affecting around 100,000 Americans that makes breathing increasingly difficult as it progresses.


The phase IIa study, conducted in China, involved 71 patients who were randomized to either receive a placebo, a daily 30mg pill, a twice-daily dose of a 30mg pill, or a daily 60 mg pill. Across all patients, the majority of side effects were mild or moderate, the company said. Those who received the highest dose law improvement in lung function compared to the placebo group. The 60mg group also saw improvements in their quality of life.


The Cambridge-based company was founded in 2014 by CEO Alex Zhavoronkov, and in 2019 first published results about designing and testing drugs with its AI platform. Earlier this year, the company published its methodology for developing ISM001-055 in Nature Biotechnology. The company is currently enrolling patients in a U.S.-based clinical trial.


These results highlight “the potential of generative AI and robotics to facilitate the discovery, design, and development of innovative therapies,” Zhavoronkov said in the announcement.

Comments

Post a Comment

Popular posts from this blog

Cell therapy weekly: partnerships for advancing cell and gene therapies

-
Image
This week: Partnerships to advance cell and gene therapies have been announced, focusing on three key areas: developing gene therapies, enhancing cell and gene therapy manufacturing and developing treatments for difficult-to-treat conditions. The news highlights:Centers of excellence for gene therapy research Advancing cell and gene therapy manufacturing Developing therapies for difficult-to-treat conditions Centers of excellence for gene therapy research The Medical Research Centre (MRC), part of UK Research and Innovation (UKRI; both Swindon, UK) is establishing two Centers of Research Excellence (CoRE) to advance therapies for untreatable diseases, each receiving up to roughly US$64 million over 14 years aiming to transform treatments for diseases such as heart disease, immune disorders and neurodegenerative diseases like Huntington’s disease. Oxford University (UK) will lead the MRC/BHF CoRE in Advanced Cardiac Therapies, which will be co-funded with the British Heart Foundati...
Read more

DBT, CSCR develop 1st human gene therapy for Haemophilia A in India

-
Image
Offering hope to around 136,000 Haemophilia A patients in India, the Department of Biotechnology (DBT), along with the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore, announced that they have successfully executed a first-in-human gene therapy using lentiviral vectors for the disease. Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal and external bleeding episodes. Although rare, India bears the world’s second-largest burden of haemophilia. Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, intravenous (IV) access in children, and low patient acceptance.The single-centre study, which enrolled five participants aged between 22 and 41 years, showed transformational results, according to scientists involved in the research. “The therapy successfully produced zero annualised bleeding rates in all five enrolled participan...
Read more